184 related articles for article (PubMed ID: 31959281)
1. T-cell co-stimulation in combination with targeting FAK drives enhanced anti-tumor immunity.
Canel M; Taggart D; Sims AH; Lonergan DW; Waizenegger IC; Serrels A
Elife; 2020 Jan; 9():. PubMed ID: 31959281
[TBL] [Abstract][Full Text] [Related]
2. Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity.
Serrels A; Lund T; Serrels B; Byron A; McPherson RC; von Kriegsheim A; Gómez-Cuadrado L; Canel M; Muir M; Ring JE; Maniati E; Sims AH; Pachter JA; Brunton VG; Gilbert N; Anderton SM; Nibbs RJ; Frame MC
Cell; 2015 Sep; 163(1):160-73. PubMed ID: 26406376
[TBL] [Abstract][Full Text] [Related]
3. IL-33 and ST2 mediate FAK-dependent antitumor immune evasion through transcriptional networks.
Serrels B; McGivern N; Canel M; Byron A; Johnson SC; McSorley HJ; Quinn N; Taggart D; Von Kreigsheim A; Anderton SM; Serrels A; Frame MC
Sci Signal; 2017 Dec; 10(508):. PubMed ID: 29208683
[TBL] [Abstract][Full Text] [Related]
4. Tumour rejection by gene transfer of 4-1BB ligand into a CD80(+) murine squamous cell carcinoma and the requirements of co-stimulatory molecules on tumour and host cells.
Mogi S; Sakurai J; Kohsaka T; Enomoto S; Yagita H; Okumura K; Azuma M
Immunology; 2000 Dec; 101(4):541-7. PubMed ID: 11122458
[TBL] [Abstract][Full Text] [Related]
5. Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumor specific cytotoxic T lymphocyte responses.
Wang LX; Mei ZY; Zhou JH; Yao YS; Li YH; Xu YH; Li JX; Gao XN; Zhou MH; Jiang MM; Gao L; Ding Y; Lu XC; Shi JL; Luo XF; Wang J; Wang LL; Qu C; Bai XF; Yu L
PLoS One; 2013; 8(5):e62924. PubMed ID: 23671644
[TBL] [Abstract][Full Text] [Related]
6. CTLA4-Ig-Based Bifunctional Costimulation Inhibitor Blocks CD28 and ICOS Signaling to Prevent T Cell Priming and Effector Function.
Goenka R; Xu Z; Samayoa J; Banach D; Beam C; Bose S; Dooner G; Forsyth CM; Lu X; Medina L; Sadhukhan R; Sielaff B; Sousa S; Tao Q; Touw D; Wu F; Kingsbury GA; Akamatsu Y
J Immunol; 2021 Mar; 206(5):1102-1113. PubMed ID: 33495237
[TBL] [Abstract][Full Text] [Related]
7. Soluble CD80 restores T cell activation and overcomes tumor cell programmed death ligand 1-mediated immune suppression.
Haile ST; Dalal SP; Clements V; Tamada K; Ostrand-Rosenberg S
J Immunol; 2013 Sep; 191(5):2829-36. PubMed ID: 23918985
[TBL] [Abstract][Full Text] [Related]
8. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
9. Restriction of PD-1 function by
Sugiura D; Maruhashi T; Okazaki IM; Shimizu K; Maeda TK; Takemoto T; Okazaki T
Science; 2019 May; 364(6440):558-566. PubMed ID: 31000591
[TBL] [Abstract][Full Text] [Related]
10. An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation.
Muik A; Altintas I; Gieseke F; Schoedel KB; Burm SM; Toker A; Salcedo TW; Verzijl D; Eisel D; Grunwitz C; Kranz LM; Vormehr M; Satijn DPE; Diken M; Kreiter S; Sasser K; Ahmadi T; Türeci Ö; Breij ECW; Jure-Kunkel M; Sahin U
Oncoimmunology; 2022; 11(1):2030135. PubMed ID: 35186440
[TBL] [Abstract][Full Text] [Related]
11. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
[TBL] [Abstract][Full Text] [Related]
12. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
[TBL] [Abstract][Full Text] [Related]
13. Tumor-Secreted Extracellular Vesicles Regulate T-Cell Costimulation and Can Be Manipulated To Induce Tumor-Specific T-Cell Responses.
Zhao X; Yuan C; Wangmo D; Subramanian S
Gastroenterology; 2021 Aug; 161(2):560-574.e11. PubMed ID: 33895168
[TBL] [Abstract][Full Text] [Related]
14. CD152 ligation by CD80 on T cells is required for the induction of unresponsiveness by costimulation-deficient antigen presentation.
Chai JG; Vendetti S; Amofah E; Dyson J; Lechler R
J Immunol; 2000 Sep; 165(6):3037-42. PubMed ID: 10975813
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant Screen Identifies Synthetic DNA-Encoding Flt3L and CD80 Immunotherapeutics as Candidates for Enhancing Anti-tumor T Cell Responses.
Thorne AH; Malo KN; Wong AJ; Nguyen TT; Cooch N; Reed C; Yan J; Broderick KE; Smith TRF; Masteller EL; Humeau L
Front Immunol; 2020; 11():327. PubMed ID: 32161596
[TBL] [Abstract][Full Text] [Related]
16. Targeting immune checkpoints in hematological malignancies.
Salik B; Smyth MJ; Nakamura K
J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
[TBL] [Abstract][Full Text] [Related]
17. Suppression of E-cadherin function drives the early stages of Ras-induced squamous cell carcinoma through upregulation of FAK and Src.
Alt-Holland A; Sowalsky AG; Szwec-Levin Y; Shamis Y; Hatch H; Feig LA; Garlick JA
J Invest Dermatol; 2011 Nov; 131(11):2306-15. PubMed ID: 21716326
[TBL] [Abstract][Full Text] [Related]
18. 4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39
Leem G; Park J; Jeon M; Kim ES; Kim SW; Lee YJ; Choi SJ; Choi B; Park S; Ju YS; Jung I; Kim S; Shin EC; Lee JY; Park SH
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33335029
[TBL] [Abstract][Full Text] [Related]
19. IL-12- and IL-2-induced tumor regression in a new murine model of oral squamous-cell carcinoma is promoted by expression of the CD80 co-stimulatory molecule and interferon-gamma.
Thomas GR; Chen Z; Enamorado I; Bancroft C; Van Waes C
Int J Cancer; 2000 May; 86(3):368-74. PubMed ID: 10760825
[TBL] [Abstract][Full Text] [Related]
20. Involvement of CD70 and CD80 intracytoplasmic domains in the co-stimulatory signal required to provide an antitumor immune response.
Douin-Echinard V; Péron JM; Lauwers-Cancès V; Favre G; Couderc B
Int Immunol; 2003 Mar; 15(3):359-72. PubMed ID: 12618480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
